Alcami, a contract development and manufacturing organization of active pharmaceutical ingredients (APIs) and drug products, has reached an agreement to be acquired by Madison Dearborn Partners, LLC (MDP), a Chicago-based private-equity firm. MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation.

Alcami’s management team, led by Chief Executive Officer, President, and Chairman, Dr. Stephan Kutzer, will continue to guide the company. The transaction is expected to be completed in the third quarter of 2018, pending customary closing conditions.

“The entire Alcami team is excited to further enhance and evolve the small to mid-size pharma growth engine,” said Dr. Kutzer in a June 1 statement. “As we enter our next stage of progress as a leading global, clinically focused and fully-integrated contract development and manufacturing organization (CDMO), we are proud to partner with MDP to expand our talented employee base and further develop our capabilities. There’s no doubt we will continue to serve our clients with dedication, innovative solutions, and our unique, flexible, transparent, and proactive approach,” he said.

Alcami is headquartered within Research Triangle Park in Durham, North Carolina, with 10 locations globally. Alcami’s services include: API development and manufacturing, solid-state chemistry, formulation development, analytical development and testing services, drug-product manufacturing (oral solid dose and parenteral), and packaging and stability services.

As part of the transaction, Ares Capital is acting as lead debt financing arranger and is maintaining a minority equity position in the company.

Source: Alcami